The effect of daily administration of IL-18 on cardiac structure and function

Perfusion

Volumn 23, Issue 4, 2008, Pages 237-242

  Platis, A ^a   Yu, Q ^a   Moore, D ^a   Khojeini, E V ^a   Tsau, P ^a   Larson, Douglas F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cardiac remodeling; IL 18; Open heart surgery

Indexed keywords

COLLAGEN; PLACEBO; RECOMBINANT INTERLEUKIN 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE COMPLIANCE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART WEIGHT; MOUSE; NONHUMAN; OPEN HEART SURGERY; PRIORITY JOURNAL; PROGNOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; CARDIAC OUTPUT; CARDIOMEGALY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HEART; INTERLEUKIN-18; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 60349085971     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659108101511     Document Type: Article

References (24)

1. Sablotzki, A, Friedrich, I, Muhling, J, et al. The systemic inflammatory response syndrome following cardiac surgery: Different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion 2002; 17: 103-109.
2. Kumar, RA, Cann, C, Hall, JE, Sudheer, PS, Wilkes, AR. Predictive value of IL-18 and SC5b-9 for neurocognitive dysfunction after cardiopulmonary bypass. Br Anaesth. 2007; 98: 317-322.
3. Yndestad, A, Holm, AM, Muller, F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003; 60: 141-146.
4. Yamaoka-Tojo, M, Tojo, T, Inomata, T, Machida, Y, Osada, K, Izumi, T. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail 2002; 8: 21-27.
5. Mallat, Z, Heymes, C, Corbaz, A, et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 2004; 18: 1752-1754.
6. Naito, Y, Tsujino, T, Fujioka, Y, Ohyanagi, M, Okamura, H, Iwasaki, T. Increased circulating interleukin-18 in patients with congestive heart failure. Heart 2002; 88: 296-297.
7. Blankenberg, S, Tiret, L, Bickel, C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
8. Blankenberg, S, Luc, G, Ducimetiere, P, et al. Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459.
9. Woldbaek, PR, Tonnessen, T, Henriksen, UL, et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma potential role in cardiac dysfunction. Cardiovasc Res 2003; 59: 122-131.
10. Woldbaek, PR, Sande, JB, Stromme, TA, et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005; 289: H708-H714.
11. Colston, JT, Boylston, WH, Feldman, MD, et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun 2007; 354: 552-558.
12. Nakanishi, K, Yoshimoto, T, Tsutsui, H, Okamura, H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001; 19: 423-474.
13. Puren, AJ, Fantuzzi, G, Gu, Y, Su, MS, Dinarello, CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101: 711-721.
14. Hoshino, T, Kawase, Y, Okamoto, M, et al. Cutting edge: IL-18-transgenic mice: In vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 2001; 166: 7014-7018.
15. Hoshino, T, Wiltrout, RH, Young, HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162: 5070-5077.
16. Hata, H, Yoshimoto, T, Hayashi, N, Hada, T, Nakanishi, K. IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2-cytokines and IL-8. Int Immunol 2004; 16: 1733-1739.
17. Finsen, AV, Christensen, G, Sjaastad, I. Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J Appl Physiol 2005; 98: 680-689.
18. Okamura, H, Tsutsi, H, Komatsu, T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
19. Reddy, P. Interleukin-18: Recent advances. Curr Opin Hematol 2004; 11: 405-410.
20. Paulukat, J, Bosmann, M, Nold, M, et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 2001; 167: 7038-7043.
21. Pomerantz, BJ, Reznikov, LL, Harken, AH, Dinarello, CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U.S.A 2001; 98: 2871-2876.
22. Chandrasekar, B, Mummidi, S, Claycomb, WC, Mestril, R, Nemer, M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005; 280: 4553-4567.
23. Schaper, J. Effects of multiple ischaemic events on human myocardium-an ultrastructural study. Eur Heart J 1988; 9 Suppl A:141-149.
24. Grobe, JL, Mecca, AP, Lingis, M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-H742.